Focus Stocks
Novo Nordisk Bulls in Charge
Published on Wednesday, 22 February 2012 12:34 Written by TradersHuddle Wire
New York, February 22nd (TradersHuddle.com) - Shares of Novo Nordisk A/S (NYSE:NVO) booked a new 52 week high today by trading above $139.83, traders are definitely monitoring Novo Nordisk's price action to see if this move attracts further buying into the stock.
Novo Nordisk A/S (NYSE:NVO) develops, produces, and markets pharmaceutical products. The Company focuses on diabetes care and offers insulin delivery systems and other diabetes products. The Denmakr based company also offers biopharmaceutical products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation.
Novo Nordisk is currently trading 0.61% versus its previous trading session close, and it has calculated support and resistance at $109.7 and $139.83 respectively. Clearly with this action this range has been penetrated, and traders will be reviewing price action to establish a new tradable range
The overall market index S&P 500 is trading lower by -0.42% from its previous trading close, which means that Novo Nordisk stock is outperforming the overall market.
Related Articles
- TradersHuddle Scanner - High Volume For Novo Nordisk
- Trade Alert - Novo Nordisk High Volume
- Novo Nordisk Higher With High Volume
- Are the Bears Taking Control over Novo Nordisk?
- Novo Nordisk plans 15 percent expansion of U.S. work force in 2012
- Novo Nordisk Honored as a Best Place to Work in New Jersey
- Up/Downgrades ( ARMH, FTE, SU, BBVA, STD, HTWR, NVO, BMC, FWRD )
- Up/Downgrades ( AGO, NRG, CIEN, JAG, NSC, TLAB, PII, NVO, THI, GPS )
- Up/Downgrades ( NVO, NSR, AEP, NLY, DQ, SCVL )
- Novo Nordisk @ Year Highs
Related Partner Headlines
- Novo Nordisk Announces FDA Approves Levemir® for Expanded Use in Children Two to Five Years of Age with Type 1 Diabetes - Benzinga
- Novo Nordisk A/S Rises On Unusually High Volume (NVO) - TheStreet.com
- Novo Nordisk A/S (NVO): Today's Featured Drugs Winner - TheStreet.com
- Caisson Biotech Enters into Development and License Agreement with Novo Nordisk - Benzinga
- Novo Nordisk A/S (NVO): Today's Featured Drugs Winner - TheStreet.com
- Novo Nordisk A/S Reaches New 52-Week High (NVO) - TheStreet.com
- Novo Nordisk A/S Stock Hits New 52-Week High (NVO) - TheStreet.com
- Novo Nordisk A/S Stock To Go Ex-dividend Tomorrow (NVO) - TheStreet.com
- Novo Nordisk A/S Stock Hits New 52-Week High (NVO) - TheStreet.com
- Novo Nordisk A/S Stock Hits New 52-Week High (NVO) - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Stocks To Watch For May 25 - Benzinga -
Top 4 Stocks In The Specialty Eateries Industry With The Highest Cash - Benzinga -
Top 4 Small-Cap Stocks In The Security Software & Services Industry With The Highest ROE - Benzinga -
Top 4 Small-Cap Stocks In The Health Care Plans Industry With The Highest Revenue - Benzinga -
Top 4 Small-Cap Stocks In The Heavy Construction Industry With The Lowest PEG Ratio - Benzinga -
Earnings Scheduled For May 25 - Benzinga -
Cramer's 'Mad Money' Recap: Big Government Not Protecting the Little Guys - TheStreet.com -
The Global Retrenchment Accelerates - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Syngenta settles atrazine litigation in the USA -
Atrazine Litigation Settled -
eMazzanti Attains Xerox Gold Partner Status -
USFS, BLM Hire Youth for Public Lands Conservation Jobs -
SCVBank Elects Scott K. Rushing as New Chairman -
Heritage Oaks Bancorp to Pay Trust Preferred Interest and Accumulated TARP Dividends -
Law Office of Brodsky & Smith, LLC Announces Investigation of Ariba, Inc. -
Following Its Record 73% Jump FY 2011 Revenue, Privately-Held Milton Security Group Reports Repeat Double-Digit Sales Growth for First Quarter 2012









